Redenlab

Redenlab was founded in 2017 to meet the evolving needs of the industry for objectively measuring meaningful outcomes in clinical trials and clinical research. The clinically motivated work of the scientific team, led by Professor Adam Vogel, focuses on cognitive-linguistic function, motor speech and voice, as well as the validation of methods for collecting and analyzing speech. This deep understanding of clinical needs, combined with knowledge of the clinical trials industry, has been the catalyst for developing a robust, evidence-based speech biomarker platform. Speech testing is a proven, reliable, sensitive, and efficient indicator of brain health and neurological integrity. Redenlab’s speech testing and analysis methods are sensitive to disease progression, treatment response, and transient effects of conditions known to alter brain health.